San Diego-primarily based Viking Therapeutics marked itself as a serious competitor in the weight loss drug current market in February just after revealing promising knowledge from the mid-phase demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when offered as a weekly injection and in March th